Cidofovir

ANTIINFECTIVES FOR SYSTEMIC USE

Key facts

Cidofovir is an ofp drug catalogued in DrugCentral. It was first approved by the FDA in 1996. DrugCentral lists 1 molecular target, including DNA polymerase catalytic subunit. Recorded indications include Acyclovir-Resistant Mucocutaneous HSV in Immunocompromised Patients and CMV Retinitis in AIDS Patients.

• Approval status: ofp (first approved 1996 by the FDA).
• Molecular targets: DNA polymerase catalytic subunit (1 listed in DrugCentral).
• Indications: Acyclovir-Resistant Mucocutaneous HSV in Immunocompromised Patients and CMV Retinitis in AIDS Patients.
• ATC code: J05AB12 (Nucleosides and nucleotides excl. reverse transcriptase inhibitors).
• Molecular formula: C8H14N3O6P; molecular weight 279.19 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (2)

• Acyclovir-Resistant Mucocutaneous HSV in Immunocompromised Patients
• CMV Retinitis in AIDS Patients

Off-label uses (1)

• Prevention of Cytomegalovirus Disease

Contraindications (3)

• Acidosis
• Kidney disease
• Severe Chronic Neutropenia

Mechanism & targets

Molecular targets (1)

Target	Gene	Action	Activity
DNA polymerase catalytic subunit	—	inhibitor	—

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1996-06-26	FDA	—	GILEAD SCIENCES INC

ATC classification

ATC code	Therapeutic hierarchy
J05AB12	ANTIINFECTIVES FOR SYSTEMIC USE › ANTIVIRALS FOR SYSTEMIC USE › DIRECT ACTING ANTIVIRALS › Nucleosides and nucleotides excl. reverse transcriptase inhibitors

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Drug resistance	428.5
Viral haemorrhagic cystitis	355.3
Adenovirus infection	326.3
Off label use	263.2
Cystitis haemorrhagic	235.4
Nephropathy toxic	183.4
Pathogen resistance	177.4
Drug ineffective for unapproved indication	158.5
BK virus infection	156.7
Cytomegalovirus infection reactivation	153.5
Cytomegalovirus infection	144.6
Renal impairment	143.3

Chemical structure

• Molecular formula: C₈H₁₄N₃O₆P
• Molecular weight: 279.19 g/mol
• CAS number: 113852-37-2
• InChIKey: VWFCHDSQECPREK-LURJTMIESA-N
• PubChem CID: 60613

NC1=NC(=O)N(C[C@@H](CO)OCP(O)(O)=O)C=C1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Cidofovir used for?

DrugCentral lists the following indications for Cidofovir: Acyclovir-Resistant Mucocutaneous HSV in Immunocompromised Patients and CMV Retinitis in AIDS Patients.

How does Cidofovir work?

Its molecular targets in DrugCentral include DNA polymerase catalytic subunit (inhibitor).

When was Cidofovir first approved?

Cidofovir was first approved by the FDA in 1996.

What is the chemical formula of Cidofovir?

Cidofovir has the molecular formula C8H14N3O6P and a molecular weight of 279.19 g/mol.

Sources

• DrugCentral drug card 639 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL152 — compound record and bioactivity
• PubChem CID 60613 — chemical identifiers
• DrugBank DB00369 — drug record
• FDA UNII JIL713Q00N — substance identity
• DailyMed: FDA labels for Cidofovir — current prescribing information (label search)
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.